Corporate governance in Diamyd Medical AB is based on the Swedish Companies Act and other relevant rules and recommendations for public companies.

In accordance with the Swedish Companies Act, the General Meeting is Diamyd Medical’s supreme decision-making body. At the General Meeting, shareholders may exercise their voting rights in key issues, for example the adoption of profit and loss statements and balance sheets, the allocation of the Company's profit, the granting of discharge from liability to the Board of Directors and CEO, the election of members of the Board of Directors and auditors, and fees to the Board of Directors and auditors. Documents are available in Swedish only.

General Meeting Documents

Pressmeddelande den 16 mars 2017


Kallelse till extra bolagsstämma 19 april 2017


Handlingar inför extra bolagsstämma 19 april 2017


Revisorns yttrande enl 13 kap. 8§ ABL


Fullmaktsformulär


The Nomination Committee of Diamyd Medical AB consists of the two largest shareholders:
Anders Essen-Möller and Bertil Lindkvist.

E-mails to the Nomination Committee:
Diamyd Medical’s auditor is BDO AB with Johan Pharmanson as the principal auditor.
The information below is related to previous rights issues in Diamyd Medical and are not to be regarded as public offers. Documents are available in Swedish only.
Informationsmaterial – Inbjudan till teckning av aktier i Diamyd Medical AB (publ) - 2016

Informationsmaterial – Inbjudan till teckning av aktier i Diamyd Medical AB (publ) - 2013

Articles of Incorporation

Articles of Incorporation for Diamyd Medical AB adopted at an Extra General Meeting of Shareholders on April 19, 2013.

   Bolagsordning  

Company Description

Company Description for Diamyd Medical AB (publ), prior to listing on Nasdaq Stockholm First North. Available as a downloadable PDF in Swedish.

   Bolagsbeskrivning